Mutant NPM1 hijacks transcriptional hub to maintain pathogenic gene programs in acute myeloid leukemia.
Xue Qing David WangDandan FanQinyu HanYiman LiuHongzhi MiaoXinyu WangQinglan LiDong ChenHaley GorePamela HimadewiGerd P PfeiferTomasz CierpickiJolanta GrembeckaJianzhong SuShasha ChongLiling WanXiaotian ZhangPublished in: Cancer discovery (2022)
Nucleophosmin (NPM1) is a ubiquitously expressed nucleolar protein with a wide range of biological functions. In 30% of acute myeloid leukemia (AML), the terminal exon of NPM1 is often found mutated, resulting in the addition of a nuclear export signal and a shift of the protein to the cytoplasm (NPM1c). AMLs carrying this mutation have aberrant expression of the HOXA/B genes, whose overexpression lead to leukemogenic transformation. Here, for the first time, we comprehensively prove NPM1c binds to a subset of active gene promoters in NPM1c AMLs, including well-known leukemia-driving genes - HOXA/B cluster genes and MEIS1. NPM1c sustains the active transcription of key target genes by orchestrating a transcription hub and maintains the active chromatin landscape by inhibiting the activity of histone deacetylases (HDACs). Together, these findings reveal the neomorphic function of NPM1c as a transcriptional amplifier for leukemic gene expression and open up new paradigms for therapeutic intervention.
Keyphrases
- acute myeloid leukemia
- genome wide
- gene expression
- genome wide identification
- transcription factor
- allogeneic hematopoietic stem cell transplantation
- dna methylation
- bioinformatics analysis
- randomized controlled trial
- genome wide analysis
- long non coding rna
- poor prognosis
- binding protein
- public health
- minimally invasive
- long noncoding rna
- amino acid
- small molecule
- protein protein